Neutropenia Induced by Ceftriaxone and Meropenem

Zay Yar Aung1, Khaled Elmagraby1, Alexandra Nica1

  • 1Acute Medicine Department, Northampton General Hospital, NHS Trust, Northampton, UK.

Insights

Rare cases of neutropenia (low white blood cell count) can occur with antibiotics like ceftriaxone and meropenem. Stopping the drugs quickly helps recovery, but severe neutropenia can lead to life-threatening sepsis.

Area of Science:

  • Pharmacology
  • Hematology
  • Infectious Diseases

Background:

  • Neutropenia is a rare, idiosyncratic adverse drug reaction, often life-threatening.
  • Ceftriaxone and meropenem are common broad-spectrum antibiotics with a generally favorable safety profile.

Purpose of the Study:

  • To report a case of neutropenia induced by ceftriaxone and meropenem in an adult patient.
  • To highlight the importance of recognizing antibiotic-induced neutropenia as a potential adverse drug effect.

Main Methods:

  • Case report presentation.
  • Clinical observation of patient's response to drug cessation.

Main Results:

  • Neutropenia resolved within 48 hours after discontinuing ceftriaxone and meropenem.
  • The case illustrates that even common antibiotics can rarely cause severe neutropenia.

Conclusions:

  • Antibiotic-induced neutropenia, though uncommon with beta-lactams and carbapenems, can lead to severe sepsis and death.
  • Prompt cessation of the offending antibiotic, supportive care, and potentially granulocyte-colony stimulating factor (G-CSF) are crucial for managing drug-induced neutropenia.

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.8K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
192
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
158